Fig. 2

Exogenous FLT-3 L treatment promotes development of lymph nodes that support HIV infection. (A) H&E staining of representative axillary lymph node sections on day 14 post-administration of rFLT-3 L compared to non-treated animals. (B) Percentage of animals with measurable LN development following experimental rFLT-3 L treatment compared to controls. (C) Quantitation of the total area of LN development utilizing whole slide imaging and area analysis using QuPath software from the H&E image of untreated (n = 7) and rFLT-3 L treatment (n = 11) groups that were combined from two separate and identical studies. (D) Infection of rFLT-3 L-treated mice with HIV-1ADA (10,000 ffu) demonstrates productive infection in the spleen and the LN as illustrated with representative tissue specimens following in situ hybridization to detect HIV gag-pol RNA. Significant differences due to treatment were determined using an unpaired two tailed Student’s T-test with Welch’s correction. Data is shown as the mean ± SEM. *p < 0.05